Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Liabilities and Shareholders Equity (2016 - 2025)

Macrogenics (MGNX) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $256.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 1.84% to $256.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $773.0 million, a 20.76% decrease, with the full-year FY2025 number at $256.8 million, down 1.84% from a year prior.
  • Liabilities and Shareholders Equity was $256.8 million for Q4 2025 at Macrogenics, down from $270.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $435.4 million in Q1 2021 to a low of $195.3 million in Q3 2022.
  • A 5-year average of $294.2 million and a median of $271.4 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 50.19% in 2022, then surged 74.03% in 2023.
  • Macrogenics' Liabilities and Shareholders Equity stood at $335.2 million in 2021, then fell by 16.34% to $280.5 million in 2022, then rose by 6.4% to $298.4 million in 2023, then dropped by 12.32% to $261.7 million in 2024, then fell by 1.84% to $256.8 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Liabilities and Shareholders Equity are $256.8 million (Q4 2025), $270.8 million (Q3 2025), and $245.4 million (Q2 2025).